'Tis the season for dupilumab?

Peters et al1 explored the efficacy of dupilumab in reducing asthma exacerbations across seasons in patients with asthma and type 2 inflammation, with and without an allergic phenotype, using post hoc data analysis from the LIBERTY ASTHMA QUEST (NCT02414854) and LIBERTY ASTHMA TRAVERSE (NCT02134028) studies. The investigators concluded that dupilumab similarly reduced severe exacerbations compared with placebo in treated patients independent of season, allergic sensitization, and baseline inhaled corticosteroid dose, supporting the use of dupilumab across seasons for all patients with type 2 asthma.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Editorial Source Type: research